FIGURE 1.
Study design. Treatment T: potential therapeutic dose of GSK'254 100 mg QD. Treatment ST: supratherapeutic dose of GSK'254 500 mg QD. Treatment P: placebo QD. Treatment M: placebo QD on Days 1–6 and a single dose of moxifloxacin 400 mg on Day 7. GSK'254, GSK3640254; QD, once daily; QTc, corrected QT. aWashout was ≥7 days minus 4 h to allow for scheduling flexibility in the clinic.